{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:48:17Z","timestamp":1785491297787,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01375"],"award-info":[{"award-number":["PI17\/01375"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CB16\/11\/00385"],"award-info":[{"award-number":["CB16\/11\/00385"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114064","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T06:18:19Z","timestamp":1670393899000},"page":"114064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?"],"prefix":"10.1016","volume":"158","author":[{"given":"Lorena","family":"Mart\u00ednez-Montesinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6241","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2022.114064_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.114064_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cger.2016.01.001","article-title":"Multimorbidity in older adults with atrial fibrillation","volume":"32","author":"Chen","year":"2016","journal-title":"Clin. Geriatr. Med\/"},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114064_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","article-title":"Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial","volume":"105","author":"Proietti","year":"2016","journal-title":"Clin. Res Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114064_bib6","first-page":"706","article-title":"Old age, high risk medication, polypharmacy: a 'trilogy' of risks in older patients with atrial fibrillation","volume":"14","author":"Wang","year":"2016","journal-title":"Pharm. Pract."},{"issue":"3","key":"10.1016\/j.biopha.2022.114064_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jgs.15712","article-title":"Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists","volume":"67","author":"Eggebrecht","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"issue":"11","key":"10.1016\/j.biopha.2022.114064_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015089","article-title":"Polypharmacy, adverse outcomes, and treatment effectiveness in patients \u226575 with atrial fibrillation","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2022.114064_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jth.12041","article-title":"The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation","volume":"11","author":"Van Den Ham","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.biopha.2022.114064_bib11","first-page":"1099","article-title":"New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs","volume":"104","author":"Garcia","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.biopha.2022.114064_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033712","article-title":"Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation","volume":"9","author":"Rivera-Caravaca","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.biopha.2022.114064_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.biopha.2022.114064_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.biopha.2022.114064_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.biopha.2022.114064_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11739-014-1096-1","article-title":"Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study","volume":"9","author":"Raparelli","year":"2014","journal-title":"Intern. Emerg. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-010-0977-0","article-title":"Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study","volume":"67","author":"Nobili","year":"2011","journal-title":"Eur. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.114064_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001257","article-title":"Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis","volume":"7","author":"Gallagher","year":"2020","journal-title":"Open Heart"},{"issue":"4","key":"10.1016\/j.biopha.2022.114064_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2022.114064_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13069","article-title":"Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality","volume":"72","author":"Rivera-Caravaca","year":"2018","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.biopha.2022.114064_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0038-1627100","article-title":"Population impact of drug interactions with warfarin: a real-world data approach","volume":"118","author":"Mart\u00edn-P\u00e9rez","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.biopha.2022.114064_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1055\/s-0040-1710592","article-title":"Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis","volume":"120","author":"Villa Zapata","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.biopha.2022.114064_bib24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ehjcvp\/pvaa117","article-title":"Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy","volume":"7","author":"Lip","year":"2021","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2022.114064_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14042","article-title":"Prevalence\/incidence of atrial fibrillation based on integrated medical\/pharmacy claims, and association with co-morbidity profiles\/multi-morbidity in a large US adult cohort","volume":"75","author":"Lip","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"11","key":"10.1016\/j.biopha.2022.114064_bib27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2022.114064_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac005","article-title":"Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","author":"Tamargo","year":"2022","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2022.114064_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31973","article-title":"Assessment of an intervention to reduce aspirin prescribing for patients receiving warfarin for anticoagulation","volume":"5","author":"Schaefer","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.biopha.2022.114064_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","article-title":"Polypill for cardiovascular disease prevention in an underserved population","volume":"381","author":"Mu\u00f1oz","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:36:29Z","timestamp":1779795389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"alternative-id":["S0753332222014536"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114064","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114064"}}